2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Biological Processes, Apoptosis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Animal Model
PAPER

5031 A C3d×CD3 T-cell engager as a modular therapeutic platform for complement-opsonized hematologic malignancies

Jisu Chae, PhD, Baskar Sivasubramanian, PhD2, Sara Lodin3, Christoph Rader, PhD4, Adrian Wiestner, MD, PhD5
1 Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States
2 Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States
3 Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States
4 Department of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical innovation & Technology, Jupiter, Florida, United States
5 Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States

Therapeutic antibodies targeting lineage-specific antigens such as CD20 and CD38 have transformed the treatment of B-cell malignancies, but their efficacy may be limited by antigen loss or treatment resistance. Complement activation by these antibodies results in covalent deposition of C3d on the tumor cell surface, creating a stable treatment-induced neoepitope. Unlike lineage-restricted targets, C3d has the potential to serve as a broadly applicable target across complement-opsonized malignancies, enabling a therapeutic platform that can be paired with different complement-fixing antibodies. Here, we developed C3d×CD3 bispecific antibodies (bsAbs) to redirect T-cell cytotoxicity toward complement-opsonized tumor cells.

A C3d×CD3 bsAb was generated using a previously discovered anti-C3d clone 5S8 and anti-CD3 clone UCHT1. The initial construct adopted a IgG1 format with knobs-into-hole and CrossMab structures for heterodimerization together with LALA-PG Fc silencing mutations to prevent engagement with other immune effector cells. A format-matched CD20×CD3 bsAb, generated by replacing the anti-C3d variable domains with the anti-CD20 sequence from epcoritamab served as a positive control.

The 1+1 C3d×CD3 bsAb demonstrated potent T-cell-mediated cytotoxicity against C3d-opsonized lymphoma cell lines. Target cells were opsonized with ofatumumab and co-cultured with negatively enriched primary human T cells (E:T = 5:1). At 1 nM, >50% target-specific killing of Jeko-1 cells was achieved by 48 hours and near-complete killing by 72 hours, comparable to both the format-matched CD20×CD3 bsAb and epcoritamab. CD8 T cells expanded >2-fold by 48 hours and >3-fold by 72 hours. By 72 hours, 73% of CD8 T cells exposed to C3dxCD3 exhibited a mature activation state (CD69⁻CD25⁺) compared to 62% for either the format-matched CD20×CD3 control bsAb or epcoritamab.  Cytotoxicity and T-cell activation were also observed in additional lymphoma cell lines (Raji and TMD8), although maximal cytotoxicity was lower than that observed in Jeko-1. Furthermore, against daratumumab-opsonized multiple myeloma cell lines (KMS-12-PE, MM1R, and RPMI-8226), the C3d×CD3 bsAb-induced approximately 50% target-specific killing by 48 hours.

To further improve target engagement, two 2+1 C3d×CD3 formats for bivalent (Bv) C3d binding were generated: Glofitamab-like Bv-Fab bsAb and a Bv-BiTE construct incorporating tandem scFvs on an Fc scaffold. Real-time cell-surface binding kinetics (HelixCyto) demonstrated that the 1+1 C3d×CD3 bsAb showed rapid dissociation rate (koff) from C3d, whereas both 2+1 constructs displayed slower dissociation kinetics, indicating prolonged target dwell time. The 2+1 Bv-BiTE bsAb achieved greater target cell killing than the other two bsAbs.

Against primary CLL B cells C3d×CD3 antibodies demonstrated suboptimal cytotoxicity despite robust T-cell activation, indicating that impaired target cell killing was not attributable to deficient T-cell activation alone. Nevertheless, pre-activation of primary T cells with CD3/CD28 Dynabeads improved C3d×CD3-mediated cytotoxicity, suggesting that stronger co-stimulation enhanced cytotoxicity.

This study advances C3d×CD3 bsAb as a novel T-cell-engaging platform that directs cytotoxicity against complement-opsonized hematologic malignancies independent of tumor lineage and supports the development of C3d-directed T-cell engagers as a versatile platform to broaden and enhance the therapeutic activity of complement-fixing antibody. Controlling co-stimulatory signaling could provide opportunities to fine tune T-cell activation and balance efficacy and tolerability.

Jisu Chae, PhD: No relevant conflicts of interest to declare.